BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

554 related articles for article (PubMed ID: 36713421)

  • 1. Cancer organoid co-culture model system: Novel approach to guide precision medicine.
    Yuan J; Li X; Yu S
    Front Immunol; 2022; 13():1061388. PubMed ID: 36713421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring Tumor-Immune Interactions in Co-Culture Models of T Cells and Tumor Organoids Derived from Patients.
    Jeong SR; Kang M
    Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Organoid technology and applications in cancer research.
    Xu H; Lyu X; Yi M; Zhao W; Song Y; Wu K
    J Hematol Oncol; 2018 Sep; 11(1):116. PubMed ID: 30219074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Organoids: approaches and utility in cancer research.
    Zhou B; Feng Z; Xu J; Xie J
    Chin Med J (Engl); 2023 Aug; 136(15):1783-1793. PubMed ID: 37365679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer modeling meets human organoid technology.
    Tuveson D; Clevers H
    Science; 2019 Jun; 364(6444):952-955. PubMed ID: 31171691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver organoids: a promising three-dimensional model for insights and innovations in tumor progression and precision medicine of liver cancer.
    Chen Y; Liu Y; Chen S; Zhang L; Rao J; Lu X; Ma Y
    Front Immunol; 2023; 14():1180184. PubMed ID: 37334366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Organoids: An intermediate modeling platform in precision oncology.
    Jin MZ; Han RR; Qiu GZ; Ju XC; Lou G; Jin WL
    Cancer Lett; 2018 Feb; 414():174-180. PubMed ID: 29174804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor organoids: applications in cancer modeling and potentials in precision medicine.
    Xu H; Jiao D; Liu A; Wu K
    J Hematol Oncol; 2022 May; 15(1):58. PubMed ID: 35551634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Organoid Models for Precision Cancer Immunotherapy.
    Sun CP; Lan HR; Fang XL; Yang XY; Jin KT
    Front Immunol; 2022; 13():770465. PubMed ID: 35450073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging organoid-immune co-culture models for cancer research: from oncoimmunology to personalized immunotherapies.
    Magré L; Verstegen MMA; Buschow S; van der Laan LJW; Peppelenbosch M; Desai J
    J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37220953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical tumor organoid models in personalized cancer therapy: Not everyone fits the mold.
    Hu LF; Yang X; Lan HR; Fang XL; Chen XY; Jin KT
    Exp Cell Res; 2021 Nov; 408(2):112858. PubMed ID: 34600901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor organoid models in precision medicine and investigating cancer-stromal interactions.
    Xu R; Zhou X; Wang S; Trinkle C
    Pharmacol Ther; 2021 Feb; 218():107668. PubMed ID: 32853629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of primary human pancreatic cancer organoids, matched stromal and immune cells and 3D tumor microenvironment models.
    Tsai S; McOlash L; Palen K; Johnson B; Duris C; Yang Q; Dwinell MB; Hunt B; Evans DB; Gershan J; James MA
    BMC Cancer; 2018 Mar; 18(1):335. PubMed ID: 29587663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient-derived organoids in human cancer: a platform for fundamental research and precision medicine.
    Qu S; Xu R; Yi G; Li Z; Zhang H; Qi S; Huang G
    Mol Biomed; 2024 Feb; 5(1):6. PubMed ID: 38342791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor organoids: synergistic applications, current challenges, and future prospects in cancer therapy.
    Qu J; Kalyani FS; Liu L; Cheng T; Chen L
    Cancer Commun (Lond); 2021 Dec; 41(12):1331-1353. PubMed ID: 34713636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reconstructing the tumor architecture into organoids.
    Luo Z; Zhou X; Mandal K; He N; Wennerberg W; Qu M; Jiang X; Sun W; Khademhosseini A
    Adv Drug Deliv Rev; 2021 Sep; 176():113839. PubMed ID: 34153370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deciphering the Tumor Microenvironment of Colorectal Cancer and Guiding Clinical Treatment With Patient-Derived Organoid Technology: Progress and Challenges.
    Li J; Liu J; Xia W; Yang H; Sha W; Chen H
    Technol Cancer Res Treat; 2024; 23():15330338231221856. PubMed ID: 38225190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Advances in three-dimensional tumor models for colorectal cancer].
    Wang CT; Zhou JL; Lin GL; Yin SY; Cong L; Zhang GN; An Y; Qiu XY
    Zhonghua Zhong Liu Za Zhi; 2023 Jun; 45(6):464-470. PubMed ID: 37355464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydrogel-based colorectal cancer organoid co-culture models.
    Luo X; Fong ELS; Zhu C; Lin QXX; Xiong M; Li A; Li T; Benoukraf T; Yu H; Liu S
    Acta Biomater; 2021 Sep; 132():461-472. PubMed ID: 33388439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer-Associated Fibroblasts Provide a Stromal Niche for Liver Cancer Organoids That Confers Trophic Effects and Therapy Resistance.
    Liu J; Li P; Wang L; Li M; Ge Z; Noordam L; Lieshout R; Verstegen MMA; Ma B; Su J; Yang Q; Zhang R; Zhou G; Carrascosa LC; Sprengers D; IJzermans JNM; Smits R; Kwekkeboom J; van der Laan LJW; Peppelenbosch MP; Pan Q; Cao W
    Cell Mol Gastroenterol Hepatol; 2021; 11(2):407-431. PubMed ID: 32932015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.